Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytosorbents (CTSO) Share-based Compensation (2016 - 2025)

Cytosorbents' Share-based Compensation history spans 15 years, with the latest figure at $886000.0 for Q4 2025.

  • Quarterly results put Share-based Compensation at $886000.0 for Q4 2025, down 3.7% from a year ago — trailing twelve months through Dec 2025 was $2.8 million (down 26.49% YoY), and the annual figure for FY2025 was $2.8 million, down 26.46%.
  • Share-based Compensation for Q4 2025 was $886000.0 at Cytosorbents, up from $488000.0 in the prior quarter.
  • In the past five years, Share-based Compensation ranged from a high of $1.7 million in Q4 2023 to a low of $488000.0 in Q3 2025.
  • The 5-year median for Share-based Compensation is $888500.0 (2024), against an average of $950619.9.
  • The sharpest move saw Share-based Compensation surged 113.59% in 2021, then crashed 51.16% in 2022.
  • Year by year, Share-based Compensation stood at $796564.0 in 2021, then grew by 9.22% to $870000.0 in 2022, then soared by 91.8% to $1.7 million in 2023, then tumbled by 44.87% to $920000.0 in 2024, then fell by 3.7% to $886000.0 in 2025.
  • According to Business Quant data, Share-based Compensation over the past three periods came in at $886000.0, $488000.0, and $571000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.